Houston COVID-19 vaccine Corbevax gets DCGI approval for use in India

First Post ^ | 29 December 2021 | Press Trust of India

[blueplum]

Houston: The Texas Children's Hospital (TCH) and Baylor College of Medicine (BCM) announced on Tuesday that Corbevax, a protein subunit Covid vaccine, has received approval from the Drugs Controller General of India (DCGI) to launch it in India.

The initial construct and production process of the vaccine antigen was developed at TCH's Centre for Vaccine Development, led by co-directors Maria Elena Bottazzi and Peter Hotez..

...TCH said the vaccine has been through phase three clinical trials with more than 3,000 subjects and was found to be safe and well-tolerated. The trials suggested a better immune response to the Ancestral-Wuhan strain of the virus as well as the delta variant compared to Covishield, developed by Oxford-AstraZeneca. None of the subjects showed severe adverse reactions to the vaccine; and adverse effects in the study were half of those from Covishield.

"TCH does not plan to make money on this, it is a gift to the world. The vaccine uses a traditional recombinant protein yeast fermentation technology, similar to that used for the recombinant hepatitis B vaccine, which has been around for 40 years. It was authorized based on superiority studies to another well- established Covid vaccine. This can be made locally all over the world, and we have now technology transferred our Texas Children's vaccine to producers in India, Indonesia, Bangladesh, Botswana, Dr Hotez said....

[Fresh Wind]

If it is effective and doesn't cause spike protein problems like those from the three US big pharma companies, what about its availability and use in the USA?

P(fda)izer will block it, in all probability.